Pharmacogenetics deals with genetically determined variation in drug response. In this context, several phase I drug-metabolizing enzymes belonging to the CYP1, CYP2 and CYP3 families of the cytochrome P450 system have a central role, affecting the metabolism of several clinically used drugs. Since genes coding for these enzymes in human populations exhibit high genetic polymorphism, they are of major clinical importance. Each of the genes encoding for main drug metabolizing CYP enzymes show a distinct variation pattern in human populations and high frequencies of altered activity variants, some of which have been extensively studied and well characterized. These results are relevant from the clinical point of view since the genetic variations at CYP2C9, CYP2C19 and CYP2D6 genes already have some clinical applications. However, in other cases the clinical relevance of polymorphism for drug action remains to be assessed and further prospective studies are necessary to fully evaluate the actual outcome and benefit of pharmacogenetic individualization.
|Translated title of the contribution||Cytochrome P450: Genetic polymorphism and pharmacological variability|
|Number of pages||12|
|Journal||Ricerca e Pratica|
|Publication status||Published - Mar 2012|
ASJC Scopus subject areas